Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet are: PLGB 53095/0068, PLGB 53095/0069, PLGB 53095/0070, PLGB 53095/0071, PLGB 53095/0072, PLGB 53095/0073.
Temodal Capsules
Temodal® 5 mg hard capsules
Temodal® 20 mg hard capsules
Temodal® 100 mg hard capsules
Temodal® 140 mg hard capsules
Temodal® 180 mg hard capsules
Temodal® 250 mg hard capsules
temozolomide
1. What Temodal is and what it is used for
2. What you need to know before you take Temodal
3. How to take Temodal
4. Possible side effects
5. How to store Temodal
6. Contents of the pack and other information
Temodal contains a medicine called temozolomide. This medicine is an antitumour agent.
Temodal is used for the treatment of specific forms of brain tumours:
Talk to your doctor, pharmacist or nurse before taking Temodal,
Do not give this medicine to children under the age of 3 years because it has not been studied. There is limited information in patients over 3 years of age who have taken Temodal.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. This is because you must not be treated with Temodal during pregnancy unless clearly indicated by your doctor.
Effective contraceptive precautions must be taken by female patients who are able to become pregnant during treatment with Temodal, and for at least 6 months following completion of treatment.
You should stop breast-feeding while receiving treatment with Temodal.
Male fertility
Temodal may cause permanent infertility. Male patients should use effective contraception and not father a child for at least 3 months after stopping treatment. It is recommended to seek advice on conservation of sperm prior to treatment.
Temodal may make you feel tired or sleepy. In this case, do not drive or use any tools or machines or cycle until you see how this medicine affects you (see section 4).
This medicine contains lactose (a kind of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Dosage and duration of treatment
Your doctor will work out your dose of Temodal. This is based on your size (height and weight) and if you have a recurrent tumour and have had chemotherapy treatment in the past.
You may be given other medicines (anti-emetics) to take before and/or after taking Temodal to prevent or control nausea and vomiting.
Patients with newly-diagnosed glioblastoma multiforme:
If you are a newly-diagnosed patient, treatment will occur in two phases:
During the concomitant phase, your doctor will start Temodal at a dose of 75 mg/m2 (usual dose). You will take this dose every day for 42 days (up to 49 days) in combination with radiotherapy. The Temodal dose may be delayed or stopped, depending on your blood counts and how you tolerate your medicine during the concomitant phase.
Once the radiotherapy is completed, you will interrupt treatment for 4 weeks. This will give your body a chance to recover.
Then, you will start the monotherapy phase.
During the monotherapy phase, the dose and way you take Temodal will be different. Your doctor will work out your exact dose. There may be up to 6 treatment periods (cycles). Each one lasts 28 days. You will take your new dose of Temodal alone once daily for the first 5 days (“dosing days”) of each cycle. The first dose will be 150 mg/m2. Then you will have 23 days without Temodal. This adds up to a 28-day treatment cycle.
After Day 28, the next cycle will begin. You will again take Temodal once daily for 5 days followed by 23 days without Temodal. The Temodal dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.
Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Temodal only:
A treatment cycle with Temodal lasts 28 days.
You will take Temodal alone once daily for the first 5 days. This daily dose depends on whether or not you have received chemotherapy before.
If you have not been previously treated with chemotherapy, your first dose of Temodal will be 200 mg/m2 once daily for the first 5 days. If you have been previously treated with chemotherapy, your first dose of Temodal will be 150 mg/m2 once daily for the first 5 days.
Then, you will have 23 days without Temodal. This adds up to a 28-day treatment cycle.
After Day 28, the next cycle will begin. You will again receive Temodal once daily for 5 days, followed by 23 days without Temodal.
Before each new treatment cycle, your blood will be tested to see if the Temodal dose needs to be adjusted. Depending on your blood test results, your doctor may adjust your dose for the next cycle.
How to take Temodal
Take your prescribed dose of Temodal once a day, preferably at the same time each day.
Take the capsules on an empty stomach; for example, at least one hour before you plan to eat breakfast. Swallow the capsule(s) whole with a glass of water. Do not open, crush or chew the capsules. If a capsule is damaged, avoid contact of the powder with your skin, eyes or nose. If you accidentally get some in your eyes or nose, flush the area with water.
Depending on the prescribed dose, you may have to take more than one capsule together, eventually with different strengths (content of active substance, in mg). The colour of the capsule cap is different for each strength (see in the table below).
Strength Colour of the cap
Temodal 5 mg hard capsules green
Temodal 20 mg hard capsules yellow
Temodal 100 mg hard capsules pink
Temodal 140 mg hard capsules blue
Temodal 180 mg hard capsules orange
Temodal 250 mg hard capsules white
You should make sure you fully understand and remember the following:
Review the dose with your doctor each time you start a new cycle, since it may be different from the last cycle.
Always take Temodal exactly as your doctor has told you. It is very important to check with your doctor or pharmacist if you are not sure. Errors in how you take this medicine may have serious health consequences.
If you accidentally take more Temodal capsules than you were told to, contact your doctor, pharmacist or nurse immediately.
Take the missed dose as soon as possible during the same day. If a full day has gone by, check with your doctor. Do not take a double dose to make up for a forgotten dose, unless your doctor tells you to do so.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediately if you have any of the following:
Temodal treatment can cause a reduction in certain kinds of blood cells. This may cause you to have increased bruising or bleeding, anaemia (a shortage of red blood cells), fever, and reduced resistance to infections. The reduction in blood cell counts is usually short-lived. In some cases, it may be prolonged and may lead to a very severe form of anaemia (aplastic anaemia). Your doctor will monitor your blood regularly for any changes, and will decide if any specific treatment is needed. In some cases, your Temodal dose will be reduced or treatment stopped.
Other side effects that have been reported are listed below:
Very Common side effects (may affect more than 1 in 10 people) are:
Common side effects (may affect up to 1 in 10 people) are:
Uncommon side effects (may affect up to 1 in 100 people) are:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.
Do not use this medicine after the expiry date which is stated on the sachet and carton. The expiry date refers to the last day of that month.
Do not store above 30 °C
Tell your pharmacist if you notice any change in the appearance of the capsules.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is temozolomide.
Temodal 5 mg hard capsules: Each capsule contains 5 mg temozolomide.
Temodal 20 mg hard capsules: Each capsule contains 20 mg temozolomide.
Temodal 100 mg hard capsules: Each capsule contains 100 mg temozolomide.
Temodal 140 mg hard capsules: Each capsule contains 140 mg temozolomide.
Temodal 180 mg hard capsules: Each capsule contains 180 mg temozolomide.
Temodal 250 mg hard capsules: Each capsule contains 250 mg temozolomide.
The other ingredients are:
capsule content:
anhydrous lactose, colloidal anhydrous silica, sodium starch glycolate type A, tartaric acid, stearic acid (see section 2 "Temodal contains lactose").
capsule shell:
Temodal 5 mg hard capsules: gelatin, titanium dioxide (E 171), sodium laurilsulfate, yellow iron oxide (E 172), indigo carmine (E 132).
Temodal 20 mg hard capsules: gelatin, titanium dioxide (E 171), sodium laurilsulfate, yellow iron oxide (E 172).
Temodal 100 mg hard capsules: gelatin, titanium dioxide (E 171), sodium laurilsulfate, red iron oxide (E 172).
Temodal 140 mg hard capsules: gelatin, titanium dioxide (E 171), sodium laurilsulfate, indigo carmine (E 132).
Temodal 180 mg hard capsules: gelatin, titanium dioxide (E 171), sodium laurilsulfate, yellow iron oxide (E 172), and red iron oxide (E 172).
Temodal 250 mg hard capsules: gelatin, titanium dioxide (E 171), sodium laurilsulfate.
printing ink:
shellac, propylene glycol (E 1520), purified water, ammonium hydroxide, potassium hydroxide, and black iron oxide (E 172).
Temodal 5 mg hard capsules have an opaque white body, an opaque green cap, and are imprinted with black ink. The cap is imprinted with “TEMODAL”. The body is imprinted with "5 mg", the Schering-Plough logo and two stripes.
Temodal 20 mg hard capsules have an opaque white body, an opaque yellow cap, and are imprinted with black ink. The cap is imprinted with “TEMODAL”. The body is imprinted with "20 mg", the Schering-Plough logo and two stripes.
Temodal 100 mg hard capsules have an opaque white body, an opaque pink cap, and are imprinted with black ink. The cap is imprinted with “TEMODAL”. The body is imprinted with "100 mg", the Schering-Plough logo and two stripes.
Temodal 140 mg hard capsules have an opaque white body, a blue cap, and are imprinted with black ink. The cap is imprinted with “TEMODAL”. The body is imprinted with "140 mg", the Schering-Plough logo and two stripes.
Temodal 180 mg hard capsules have an opaque white body, an opaque orange cap, and are imprinted with black ink. The cap is imprinted with “TEMODAL”. The body is imprinted with "180 mg", the Schering-Plough logo and two stripes.
Temodal 250 mg hard capsules have an opaque white body and cap, and are imprinted with black ink. The cap is imprinted with “TEMODAL”. The body is imprinted with "250 mg", the Schering-Plough logo and two stripes.
The hard capsules (capsules) for oral use are individually sealed in sachets and dispensed in cartons containing 5 or 20 hard capsules.
Not all pack sizes may be marketed.
Marketing Authorisation Holder:
Manufacturer:
For any information about this medicine, please contact:
This leaflet was last revised in August 2023.
© 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
PIL.TEM.23.GB.8425.IAin-011G.RCN026007